Interstitial laser photochemotherapy with new anthrapyrazole drugs for the treatment of xenograft tumors.

Abstract

Photodynamic therapy (PDT) with lasers and new dyes has gained popularity in recent years as a minimally invasive technique with high tumoricidal effects in vitro and in some cancer patients. However, because new laser dyes are not FDA approved at present, the clinical evaluation of PDT may be years away. During the past 6 years we have used laser alone for photothermal ablation in both preclinical studies and in a large number of patients with an observed 60% tumor response rate. The 40% treatment failure led us to explore the possibility of combined therapy with lasers and standard chemotherapeutic drugs. We have recently tested a promising preclinical alternative using implantation of a bare 600-microns KTP 532 laser fiberoptic in multiple tumor sites 30 min after intratumor injection of the anthrapyrazole DUP-941. As a control, this drug was injected in 3 sites of P3 human squamous cell tumor transplants in nude mice, which led to tumor stasis without regression. Similar 400-600 mm3 tumors exposed to laser illumination alone (0.8 W for 5 sec) at multiple sites resulted in tumor regrowth after 10 weeks in 80% of the animals. However, combining interstitial laser illumination with intratumor DUP-941 injections led to complete tumor regression in 85% of the mice. We propose that intratumor drug injection followed by interstitial laser fiberoptic treatment represents a potentially useful new method for tumor ablation in advanced cancer patients.

Cite this paper

@article{Paiva1995InterstitialLP, title={Interstitial laser photochemotherapy with new anthrapyrazole drugs for the treatment of xenograft tumors.}, author={Marcos B. Paiva and Romaine E. Saxton and Gary A Letts and Pui See Chung and Jacques Soudant and Q Vanderwerf and Dan J. Castro}, journal={Journal of clinical laser medicine & surgery}, year={1995}, volume={13 5}, pages={307-13} }